JP3993168B2 - ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 - Google Patents
ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 Download PDFInfo
- Publication number
- JP3993168B2 JP3993168B2 JP2003536411A JP2003536411A JP3993168B2 JP 3993168 B2 JP3993168 B2 JP 3993168B2 JP 2003536411 A JP2003536411 A JP 2003536411A JP 2003536411 A JP2003536411 A JP 2003536411A JP 3993168 B2 JP3993168 B2 JP 3993168B2
- Authority
- JP
- Japan
- Prior art keywords
- strain
- ncimb41114
- lactobacillus pentosus
- lactobacillus
- pentosus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000186684 Lactobacillus pentosus Species 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims description 20
- 241000894006 Bacteria Species 0.000 claims abstract description 28
- 206010007134 Candida infections Diseases 0.000 claims abstract description 12
- 201000003984 candidiasis Diseases 0.000 claims abstract description 12
- 235000016709 nutrition Nutrition 0.000 claims description 17
- 241000222122 Candida albicans Species 0.000 claims description 14
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 14
- 239000004098 Tetracycline Substances 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 229960002180 tetracycline Drugs 0.000 claims description 12
- 229930101283 tetracycline Natural products 0.000 claims description 12
- 235000019364 tetracycline Nutrition 0.000 claims description 12
- 150000003522 tetracyclines Chemical class 0.000 claims description 12
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 206010012735 Diarrhoea Diseases 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 230000002550 fecal effect Effects 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 1
- -1 pessary Substances 0.000 claims 1
- 239000006041 probiotic Substances 0.000 abstract description 18
- 235000018291 probiotics Nutrition 0.000 abstract description 18
- 230000000529 probiotic effect Effects 0.000 abstract description 15
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract description 13
- 230000012010 growth Effects 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 208000012868 Overgrowth Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 244000000010 microbial pathogen Species 0.000 abstract description 2
- 208000007027 Oral Candidiasis Diseases 0.000 abstract 1
- 241000287411 Turdidae Species 0.000 abstract 1
- 241000186660 Lactobacillus Species 0.000 description 20
- 229940039696 lactobacillus Drugs 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000003115 biocidal effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 229940095731 candida albicans Drugs 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229910001873 dinitrogen Inorganic materials 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229960000988 nystatin Drugs 0.000 description 3
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000012449 sabouraud dextrose agar Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(i)連続培養系:3つのケモスタットを並行して準備した;各々を窒素ガスの下、37℃、pH6.5および0.066h−1の希釈速度で維持した。これらの条件は、ヒト結腸の末端領域において典型的に見出される条件に類似するように設定された。これらのケモスタットに、:酵母エキスを2(g/蒸留水1l;以下同じ)、ペプトン水を2、NaClを0.1、K2HPO4を0.04、KH2PO4を0.04、MgSO4・7H2Oを0.01、CaCl2・H2Oを0.01、NaHCO3を2、Tween 80を2、ヘミンを0.05、ビタミンK1を0.01、システイン・HClを0.5、胆汁塩を0.5、グルコースを0.4、デンプンを3、ペクチンを2およびアラビノガラクタンを1含有する増殖調節培地を供給した。この培地を121℃で30分間オートクレーブ処理し、まだ熱いうちに、窒素ガスの下に置いた。培地を冷却した後、1g/lの濾過滅菌テトラサイクリンまたは1g/lの濾過滅菌ナイスタチン(nystatin)を培地用リザーバに無菌的に添加した。抗生物質が添加されないコントロール用対照ケモスタットも稼働させた。
実験1:カンジダ・アルビカンスおよびケモスタットから単離したラクトバシルスを、それぞれ、Sabouraud Dexiroseブロス(Oxoid)およびMRSブロス(Oxoid)において一晩増殖させた。次に、各々の1mlを、以下の培地成分を収容する750mlバッチ発酵槽に接種した:酵母エキスを2(g/蒸留水1l;以下同じ)、ペプトン水を2、NaClを0.1、K2HPO4を0.04、KH2PO4を0.04、MgSO4・7H2Oを0.01、CaCl2・H2Oを0.01、NaHCO3を2、Tween 80を2、システイン・HClを0.5およびグルコース1.0。培地を121℃で30分間オートクレーブ処理し、まだ熱いうちに窒素ガスの下に置いた。混合培養発酵を37℃およびpH6.5で嫌気的に維持した。定時の試料を48時間にわたって採取し、顕微鏡で細胞数を計測した。培養物の同一性は、表現型および生化学的形質により確認した。発酵の最後に1mlを発酵槽から取り出し、連続的に希釈してMRSおよびSabouraud Dextrose寒天に塗布し、嫌気的に48時間培養した。
(他に記述しない限り、全ての化学薬品はSigma Chemical Co.から購入した。)
Claims (16)
- 受託番号NCIMB41114として寄託されているラクトバシルス・ペントサス(Lactobacillus pentosus)株。
- 生の、弱毒化された、または死滅されたラクトバシルス・ペントサスNCIMB41114株および汎用の担体を含む栄養性組成物。
- 組成物のグラム当たり105〜1011cfuのラクトバシルス・ペントサスNCIMB41114株を含む、請求項2に記載の栄養性組成物。
- 1日用量において106〜1012cfuのラクトバシルス・ペントサスNCIMB41114株を提供する、請求項2または3に記載の栄養性組成物。
- 生の、弱毒化された、または死滅されたラクトバシルス・ペントサスNCIMB41114株および汎用の担体を含む医薬組成物。
- 組成物のグラム当たり105〜1011cfuのラクトバシルス・ペントサスNCIMB41114株を含む、請求項5に記載の医薬組成物。
- 1日用量において106〜1012cfuのラクトバシルス・ペントサスNCIMB41114株を提供する、請求項5または6に記載の医薬組成物。
- 錠剤、カプセル、インプラント、坐剤、ペッサリー、粉末、溶液、ゲル、または細菌懸濁液の形態にある、請求項5から7のいずれか1項に記載の医薬組成物。
- ラクトバシルス・ペントサスNCIMB41114株の医薬としての使用。
- カンジダ症を予防または治療するための医薬の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- 健常腸内フローラを促進するための、および過敏性腸症候群またはその症状を予防または治療するための医薬の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- 下痢または他の胃腸障害を予防または治療するための医薬の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- カンジダ症を予防または治療するための栄養性配合物の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- 健常腸内フローラを促進するための、および過敏性腸症候群またはその症状を予防または治療するための栄養性配合物の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- 下痢または他の胃腸障害を予防または治療するための栄養性配合物の製造におけるラクトバシルス・ペントサスNCIMB41114株の使用。
- 糞便由来細胞培養物を殺菌レベルのテトラサイクリンの存在下において培養させ、生存可能な乳酸菌細胞を前記培養物から集めることを含む方法によって得られる、請求項1に記載のラクトバシルス・ペントサス株。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0124580.2A GB0124580D0 (en) | 2001-10-12 | 2001-10-12 | New composition |
PCT/EP2002/011428 WO2003033681A2 (en) | 2001-10-12 | 2002-10-11 | Composition comprising a lactobacillus pentosus strain and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007162144A Division JP2007308504A (ja) | 2001-10-12 | 2007-06-20 | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005505298A JP2005505298A (ja) | 2005-02-24 |
JP3993168B2 true JP3993168B2 (ja) | 2007-10-17 |
Family
ID=9923753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003536411A Expired - Fee Related JP3993168B2 (ja) | 2001-10-12 | 2002-10-11 | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 |
JP2007162144A Pending JP2007308504A (ja) | 2001-10-12 | 2007-06-20 | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007162144A Pending JP2007308504A (ja) | 2001-10-12 | 2007-06-20 | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7125708B2 (ja) |
EP (1) | EP1436380B1 (ja) |
JP (2) | JP3993168B2 (ja) |
CN (1) | CN1297653C (ja) |
AT (1) | ATE302265T1 (ja) |
AU (1) | AU2002350530A1 (ja) |
BR (1) | BR0213189A (ja) |
CA (1) | CA2459572A1 (ja) |
DE (1) | DE60205646T2 (ja) |
DK (1) | DK1436380T3 (ja) |
ES (1) | ES2245411T3 (ja) |
GB (1) | GB0124580D0 (ja) |
WO (1) | WO2003033681A2 (ja) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
GB0308104D0 (en) * | 2003-04-08 | 2003-05-14 | Novartis Nutrition Ag | Organic compounds |
EP1481681A1 (en) * | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
IE20030773A1 (en) * | 2003-10-17 | 2005-04-20 | Teagasc Agric Food Dev Authori | Use of probiotic bacteria in the treatment of infection |
SE0400998D0 (sv) | 2004-04-16 | 2004-04-16 | Cooding Technologies Sweden Ab | Method for representing multi-channel audio signals |
JP4515157B2 (ja) * | 2004-05-28 | 2010-07-28 | サントリーホールディングス株式会社 | 免疫調節作用を有する乳酸菌 |
CA2567976C (en) * | 2004-05-28 | 2012-06-05 | Suntory Limited | A composition having immunoregulating activities comprising lactobacillus pentosus |
JP5199551B2 (ja) * | 2006-07-06 | 2013-05-15 | サンスター株式会社 | カンジダ菌感染に基づく疾患の予防又は改善剤 |
JP5128183B2 (ja) * | 2007-05-31 | 2013-01-23 | カゴメ株式会社 | 新規乳酸菌株、発酵飲食品および発酵飲食品の製造方法 |
CN101677608B (zh) * | 2007-05-31 | 2013-02-27 | 可果美株式会社 | 发酵饮食品及其制造方法 |
US20110027348A1 (en) * | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
CN102223809A (zh) * | 2008-09-17 | 2011-10-19 | 阿格拉奎斯特公司 | 利用枯草芽孢杆菌菌株以增强动物健康的方法 |
JP2010095465A (ja) | 2008-10-16 | 2010-04-30 | House Wellness Foods Kk | 乳酸菌含有免疫賦活用組成物 |
IT1397566B1 (it) * | 2009-05-27 | 2013-01-16 | Probiotical Spa | Lactobacillus pentosus produttore di batteriocine, composizioni alimentari e farmaceutiche contenenti lo stesso e relativo uso |
PL3564357T3 (pl) | 2010-02-01 | 2022-08-08 | Rebiotix, Inc. | Bakterioterapia zapalenia jelita grubego z clostridium difficile |
IT1398553B1 (it) * | 2010-03-08 | 2013-03-01 | Probiotical Spa | Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario. |
ES2550059T3 (es) | 2010-03-17 | 2015-11-04 | Bayer Cropscience Lp | Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales |
US9308226B2 (en) | 2010-08-04 | 2016-04-12 | Thomas Julius Borody | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
WO2012031186A1 (en) | 2010-09-03 | 2012-03-08 | Wisconsin Pharmacal Company, Llc. | Prebiotic suppositories |
JP6002582B2 (ja) * | 2011-01-25 | 2016-10-05 | 株式会社明治 | ガストリン産生抑制剤およびそれを含有する食品組成物 |
US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
ITMI20110679A1 (it) * | 2011-04-20 | 2012-10-21 | Giovanni Mogna | Composizione comprendente batteri probiotici in grado di ripristinare l effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell iperacidita gastrica. |
US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
FR2999601B1 (fr) * | 2012-12-17 | 2015-01-30 | Urgo Lab | Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis |
KR20150143803A (ko) | 2013-04-17 | 2015-12-23 | 산토리 홀딩스 가부시키가이샤 | 락토바실러스속 균 함유 조성물 |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
KR102291174B1 (ko) | 2013-06-05 | 2021-08-18 | 리바이오틱스, 인코퍼레이티드 | 미생물상 복원 요법(mrt), 조성물 및 제조방법 |
TWI643626B (zh) * | 2013-08-12 | 2018-12-11 | 西班牙商巨妮亞實驗室有限公司 | 作為益生菌之乳桿菌屬菌株 |
EP3049070A4 (en) * | 2013-09-27 | 2017-04-05 | Ira Milton Trachtman | Compositions and methods for treatment and prophylaxis of gastrointestinal diseases |
CN114159476A (zh) | 2015-05-14 | 2022-03-11 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
KR102358879B1 (ko) | 2015-05-22 | 2022-02-08 | 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 | 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법 |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
KR102066242B1 (ko) | 2015-06-09 | 2020-01-14 | 리바이오틱스, 인코퍼레이티드 | 미생물상 복원 치료(mrt) 조성물 및 제조 방법 |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
KR101761506B1 (ko) * | 2015-08-13 | 2017-07-25 | 한국식품연구원 | 락토바실러스 펜토서스를 유효성분으로 포함하는 Th1-매개 면역 질환, Th17-매개 면역 질환, 또는 Th2-매개 면역 질환의 예방, 개선, 또는 치료용 조성물 |
BE1023643B1 (nl) * | 2016-03-21 | 2017-06-01 | Yun NV | Vaginale preparaten voor het onderhouden en / of herstellen van een gezonde vrouwelijke microbiota |
EP3470075B1 (en) | 2016-06-13 | 2024-03-20 | Murata Manufacturing Co., Ltd. | Antimicrobial agent for antifungal therapeutic use |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
BE1024425B9 (nl) * | 2016-06-21 | 2018-03-26 | Yun NV | Dermatologische preparaten voor het onderhouden en/of herstellen van een gezonde huidmicrobiota |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
WO2018071536A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating primary sclerosing cholangitis and related disorders |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
CN106727870A (zh) * | 2016-12-01 | 2017-05-31 | 北京伊科生态科技研究院 | 一种治疗酵母菌感染的复合益生菌洗液及其制备方法 |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
CN110996917A (zh) | 2017-05-26 | 2020-04-10 | 克雷斯顿沃控股公司 | 包含基于粪便微生物的治疗剂的冻干组合物及其制造和使用方法 |
AU2018313766A1 (en) | 2017-08-07 | 2020-02-20 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
CN107898815A (zh) * | 2017-12-07 | 2018-04-13 | 生物源生物技术(深圳)股份有限公司 | 一种动物用灭活乳酸菌制剂及其用途 |
CN107815432B (zh) * | 2017-12-07 | 2021-09-28 | 广州柏芳生物科技有限公司 | 一种人用灭活乳酸菌制剂及其用途 |
WO2019212330A1 (en) * | 2018-04-30 | 2019-11-07 | N.V. Nutricia | Formula with a specific beta-lactoglobulin peptide |
WO2019212329A1 (en) * | 2018-04-30 | 2019-11-07 | N.V. Nutricia | Formula with specific beta-lactoglobulin peptides |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
EP3856212A1 (en) | 2018-09-27 | 2021-08-04 | Finch Therapeutics Holdings LLC | Compositions and methods for treating epilepsy and related disorders |
CN115058367B (zh) * | 2022-07-06 | 2023-06-16 | 陕西省微生物研究所 | 一株戊糖乳杆菌(Lactobacillus pentosus)068-1及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR4430M (ja) * | 1965-04-16 | 1966-09-19 | ||
GB1190386A (en) | 1966-06-28 | 1970-05-06 | Green Cross Corp | Process for producing the Lactic Acid Bacteria Drugs |
US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
IT1227154B (it) * | 1988-08-05 | 1991-03-19 | A Tosi Farmaceutici S R L Nova | Composizioni farmaceutiche per uso ginecologico a base di lattobacilli |
SE469875C (sv) * | 1991-07-25 | 1997-04-14 | Probi Ab | Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen |
ATE153063T1 (de) | 1992-07-06 | 1997-05-15 | Nestle Sa | Milchbakterien |
PE9795A1 (es) * | 1994-01-13 | 1995-05-04 | Nestle Sa | Composicion y procedimiento util para reducir el contenido calorico graso de alimentos que contienen grasas o aceites |
ECSP941055A (es) * | 1994-01-13 | 1994-11-16 | Nestle Sa | Composicion y procedimiento utilizado para estabilizar proteinas de huevo sujetas a tratamiento termico subsiguiente |
PE8795A1 (es) * | 1994-01-13 | 1995-04-19 | Nestle Sa | Procedimiento para la preparacion de alimentos que tienen un contenido reducido de productos lacteos fermentados y/o material de fruta y composicion util para este |
JP3034451B2 (ja) * | 1995-09-12 | 2000-04-17 | プリマハム株式会社 | 腸管由来の乳酸菌及びそれを利用した非加熱食肉製品 |
JPH09110707A (ja) * | 1995-10-12 | 1997-04-28 | Wakamoto Pharmaceut Co Ltd | 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤 |
JPH09263539A (ja) * | 1996-03-29 | 1997-10-07 | Nichinichi Seiyaku Kk | 抗真菌作用を有する皮膚疾患治療剤 |
MXPA99007378A (es) | 1997-02-11 | 2005-04-19 | Entpr Ireland | Cepas probioticas de lactobacillus salivarius y agentes antimicrobianos obtenidos a partir de lasmismas. |
US6093394A (en) * | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
SE510753C2 (sv) * | 1997-08-05 | 1999-06-21 | Probi Ab | Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod |
EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
PT956858E (pt) * | 1998-04-30 | 2002-04-29 | Renata Maria Anna Caval Vesely | Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais |
US6461607B1 (en) | 1998-08-24 | 2002-10-08 | Ganeden Biotech, Inc. | Probiotic, lactic acid-producing bacteria and uses thereof |
ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
CZ20013269A3 (cs) | 1999-03-11 | 2002-04-17 | Société des Produits Nestlé S. A. | Bakterie mléčného kvaąení |
AP1433A (en) | 1999-04-02 | 2005-06-20 | Friedshelf 339 Pty Limited | Baking mixes which contain flour and have an enhanced shelf life and method and means of preparing same. |
EP1084709A1 (en) * | 1999-09-17 | 2001-03-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Oral recombinant lactobacilli vaccines |
ES2239622T3 (es) | 1999-10-26 | 2005-10-01 | Societe Des Produits Nestle S.A. | Bacterias del acido lactico para el tratamiento y/o profilaxis de giardiasis. |
AUPQ415899A0 (en) | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
SG106572A1 (en) * | 1999-12-02 | 2004-10-29 | Nestle Sa | Production of hydrolysate seasoning |
EP1110555A1 (fr) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Agent anti-adhesion de la flore pathogene de la peau |
GB2369777B (en) * | 2000-10-05 | 2004-10-27 | St Ivel Ltd | Food products with antimicrobial lactic acid bacteria |
-
2001
- 2001-10-12 GB GBGB0124580.2A patent/GB0124580D0/en not_active Ceased
-
2002
- 2002-10-11 EP EP02785202A patent/EP1436380B1/en not_active Expired - Lifetime
- 2002-10-11 WO PCT/EP2002/011428 patent/WO2003033681A2/en active IP Right Grant
- 2002-10-11 JP JP2003536411A patent/JP3993168B2/ja not_active Expired - Fee Related
- 2002-10-11 DE DE60205646T patent/DE60205646T2/de not_active Expired - Fee Related
- 2002-10-11 CA CA002459572A patent/CA2459572A1/en not_active Abandoned
- 2002-10-11 AU AU2002350530A patent/AU2002350530A1/en not_active Abandoned
- 2002-10-11 AT AT02785202T patent/ATE302265T1/de not_active IP Right Cessation
- 2002-10-11 DK DK02785202T patent/DK1436380T3/da active
- 2002-10-11 CN CNB02820204XA patent/CN1297653C/zh not_active Expired - Fee Related
- 2002-10-11 BR BR0213189-7A patent/BR0213189A/pt not_active IP Right Cessation
- 2002-10-11 US US10/491,381 patent/US7125708B2/en not_active Expired - Fee Related
- 2002-10-11 ES ES02785202T patent/ES2245411T3/es not_active Expired - Lifetime
-
2007
- 2007-06-20 JP JP2007162144A patent/JP2007308504A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005505298A (ja) | 2005-02-24 |
DK1436380T3 (da) | 2005-10-17 |
ES2245411T3 (es) | 2006-01-01 |
EP1436380A2 (en) | 2004-07-14 |
CN1568365A (zh) | 2005-01-19 |
DE60205646D1 (de) | 2005-09-22 |
CA2459572A1 (en) | 2003-04-24 |
DE60205646T2 (de) | 2006-05-18 |
JP2007308504A (ja) | 2007-11-29 |
AU2002350530A1 (en) | 2003-04-28 |
GB0124580D0 (en) | 2001-12-05 |
ATE302265T1 (de) | 2005-09-15 |
WO2003033681A3 (en) | 2003-09-04 |
BR0213189A (pt) | 2004-08-31 |
CN1297653C (zh) | 2007-01-31 |
EP1436380B1 (en) | 2005-08-17 |
US7125708B2 (en) | 2006-10-24 |
US20050031601A1 (en) | 2005-02-10 |
WO2003033681A2 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3993168B2 (ja) | ラクトバシルス・ペントサス株を含む組成物およびそれらの使用 | |
US11225641B2 (en) | Probiotic Bifidobacterium strain | |
EP1137423B1 (en) | Oral administration of lactobacillus for the treatment and prevention of urogenital infection | |
EP2179028B1 (en) | A novel strain of bifidobacterium and active peptides against rotavirus infections | |
TWI627276B (zh) | 新穎之卷曲乳酸桿菌(lactobacillus crispatus)菌株 | |
EP1796698B1 (en) | Strain of lactobacillus acidophilus having analgesic properties in the gastrointestinal system | |
AU2018282018B2 (en) | Compositions and methods for reducing flatulence | |
CN113832077A (zh) | 鼠李糖乳杆菌及其应用 | |
US8021883B2 (en) | Antibiotic-sensitive lactic acid bacteria strains | |
WO2018112739A1 (zh) | 一种假小链状双歧杆菌及其培养方法和应用 | |
CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
JP2008054556A (ja) | 免疫賦活作用及び/又はアレルギー抑制作用を有し、且つ胃液耐性を有する新規乳酸菌 | |
CN117866831A (zh) | 一种鼠李糖乳酪杆菌及其应用 | |
US11045507B2 (en) | Bifidobacterium animalis AMT30 strain and the composition containing the strain of Bifidobacterium animalis AMT30 | |
CN117004503B (zh) | 一株唾液联合乳杆菌mb1及其在制备助睡眠和调理肠胃食品药品中的应用 | |
RU2491336C1 (ru) | Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактерийных препаратов и биологически активных добавок, предназначенных для коррекции микрофлоры людей старше 14 лет, способ его получения, биологически активная добавка к пище для коррекции микрофлоры желудочно-кишечного тракта людей старше 14 лет и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта людей старше 14 лет | |
TW201016847A (en) | A strain of Lactobacillus plantarum and its use for inhibiting Helicobacter pylori growth | |
ES2891536T3 (es) | Cepa Bifidobacterium animalis AMT30 y composición que contiene la cepa de Bifidobacterium animalis AMT30 | |
CN114574405B (zh) | 植物乳杆菌菌株wka86及其在制备防治口臭制品方面的用途与制品 | |
KR100400411B1 (ko) | 질염 치료용 생균제제 | |
RU2491331C1 (ru) | Консорциум бифидобактерий и лактобацилл, используемый для приготовления бактерийных препаратов и биологически активных добавок к пище, предназначенных для коррекции микрофлоры желудочно-кишечного тракта детей в возрасте до 3-х лет, и способ его получения, биологически активная добавка к пище и бактериальный препарат для лечения дисбиотических состояний желудочно-кишечного тракта детей в возрасте до 3-х лет | |
CN117866841A (zh) | 一株粪肠球菌xy2及其在制备调理肠胃和改善痛风食品药品中的应用 | |
WO2021256968A1 (ru) | Штамм Bifidobacterium bifidum 8, используемый в качестве пробиотика | |
EA043487B1 (ru) | Штамм bifidobacterium bifidum 8, используемый в качестве пробиотика | |
CN117866839A (zh) | 一株粪肠球菌xy7及其在制备抗炎和改善痛风食品药品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060711 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061004 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061017 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070620 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070717 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070725 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100803 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |